An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
← catalyst calendarNCT06768671 · readout in 40 d
Sponsored by MoonLake Immunotherapeutics AG (industry) · MLTX — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
35estimated
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-30 | actual | When the study began enrolling |
| Primary completion | 2026-09-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-28 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa
Intervention
- Drug: Sonelokimab
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK) of sonelokimab in adolescents
measured Week 24
Adverse events (AEs) following treatment with sonelokimab in adolescents
measured Week 24
Discontinuation of sonelokimab treatment due to AEs
measured Week 24
Clinically significant changes in clinical laboratory parameters
measured Week 24
Clinically significant changes in vital signs
measured Week 24
Clinically significant changes in standard 12-lead electrocardiogram (ECG) intervals
measured Week 24
Permalink · MLTX's whole pipeline · Catalyst calendar · Every registered study · What changed